Referencias bibliográficas

1. Bloem BR, Okun MS, Klein C. Parkinson's disease. Lancet. 2021 Jun 12;397(10291):2284-303. [Pubmed]
2. Pfeiffer RF. Non-motor symptoms in Parkinson's disease. Parkinsonism Relat Disord. 2016 Jan;22 Suppl 1:S119-22. [Pubmed]
3. Ascherio A, Schwarzschild MA. The epidemiology of Parkinson's disease: risk factors and prevention. Lancet Neurol. 2016 Nov;15(12):1257-72. [Pubmed]
4. Nalls MA, Blauwendraat C, Vallerga CL, Heilbron K, Bandres-Ciga S, Chang D, et al.; 23andMe Research Team; System Genomics of Parkinson's Disease Consortium; International Parkinson's Disease Genomics Consortium. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 2019 Dec;18(12):1091-02. [Pubmed]
5. Dickson DW. Neuropathology of Parkinson disease. Parkinsonism Relat Disord. 2018 Jan;46 Suppl 1(Suppl 1):S30-S33. [Pubmed]
6. Dickson DW. Parkinson's disease and parkinsonism: neuropathology. Cold Spring Harb Perspect Med. 2012 Aug 1;2(8):a009258. [Pubmed]
7. Shahmoradian SH, Lewis AJ, Genoud C, Hench J, Moors TE, Navarro PP, et al. Lewy pathology in Parkinson's disease consists of crowded organelles and lipid membranes. Nat Neurosci. 2019 Jul;22(7):1099-109. [Pubmed]
8. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003 Mar-Apr;24(2):197-211. [Pubmed]
9. Noyce AJ, Bestwick JP, Silveira-Moriyama L, Hawkes CH, Giovannoni G, Lees AJ, Schrag A. Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann Neurol. 2012 Dec;72(6):893-901. [Pubmed]
10. Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. Parkinson disease. Nat Rev Dis Primers. 2017 Mar 23;3:17013. [Pubmed]
11. Lashuel HA, Overk CR, Oueslati A, Masliah E. The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci. 2013 Jan;14(1):38-48. [Pubmed]
12. Barbour R, Kling K, Anderson JP, Banducci K, Cole T, Diep L, et al. Red blood cells are the major source of alpha-synuclein in blood. Neurodegener Dis. 2008;5(2):55-9. [Pubmed]
13. Borsche M, Pereira SL, Klein C, Grünewald A. Mitochondria and Parkinson's Disease: Clinical, Molecular, and Translational Aspects. J Parkinsons Dis. 2021;11(1):45-60. [Pubmed]
14. Dehay B, Martínez-Vicente M, Caldwell GA, Caldwell KA, Yue Z, Cookson MR, et al. Lysosomal impairment in Parkinson's disease. Mov Disord. 2013 Jun;28(6):725-32. [Pubmed]
15. Li X, Sundquist J, Sundquist K. Subsequent risks of Parkinson disease in patients with autoimmune and related disorders: a nationwide epidemiological study from Sweden. Neurodegener Dis. 2012;10(1-4):277-84. [Pubmed]
16. Sulzer D, Alcalay RN, Garretti F, Cote L, Kanter E, Agin-Liebes J, et al. T cells from patients with Parkinson's disease recognize α-synuclein peptides. Nature. 2017 Jun 29;546(7660):656-61. Erratum in: Nature. 2017 Sep 13;549(7671):292. [Pubmed]
17. Boertien JM, Pereira PAB, Aho VTE, Scheperjans F. Increasing Comparability and Utility of Gut Microbiome Studies in Parkinson's Disease: A Systematic Review. J Parkinsons Dis. 2019;9(s2):S297-S312. [Pubmed]
18. Surmeier DJ, Schumacker PT, Guzman JD, Ilijic E, Yang B, Zampese E. Calcium and Parkinson's disease. Biochem Biophys Res Commun. 2017 Feb 19;483(4):1013-9. [Pubmed]
19. Saheki Y, De Camilli P. Synaptic vesicle endocytosis. Cold Spring Harb Perspect Biol. 2012 Sep 1;4(9):a005645. [Pubmed]
20. Nguyen M, Wong YC, Ysselstein D, Severino A, Krainc D. Synaptic, Mitochondrial, and Lysosomal Dysfunction in Parkinson's Disease. Trends Neurosci. 2019 Feb;42(2):140-9. [Pubmed]
21. Masato A, Plotegher N, Boassa D, Bubacco L. Impaired dopamine metabolism in Parkinson's disease pathogenesis. Mol Neurodegener. 2019 Aug 20;14(1):35. [Pubmed]
22. Fearon C, Lang AE, Espay AJ. The Logic and Pitfalls of Parkinson's Disease as "Brain-First" Versus "Body-First" Subtypes. Mov Disord. 2021 Mar;36(3):594-8. [Pubmed]
23. Wakabayashi K. Where and how alpha-synuclein pathology spreads in Parkinson's disease. Neuropathology. 2020 Oct;40(5):415-25. [Pubmed]
24. Breid S, Bernis ME, Babila JT, Garza MC, Wille H, Tamgüney G. Neuroinvasion of α-Synuclein Prionoids after Intraperitoneal and Intraglossal Inoculation. J Virol. 2016 Sep 29;90(20):9182-93. [Pubmed]
25. Espay AJ, Kalia LV, Gan-Or Z, Williams-Gray CH, Bedard PL, Rowe SM, et al. Disease modification and biomarker development in Parkinson disease: Revision or reconstruction? Neurology. 2020 Mar 17;94(11):481-94. [Pubmed]
26. Grünewald A, Rygiel KA, Hepplewhite PD, Morris CM, Picard M, Turnbull DM. Mitochondrial DNA Depletion in Respiratory Chain-Deficient Parkinson Disease Neurons. Ann Neurol. 2016 Mar;79(3):366-78. [Pubmed]
27. Kamath T, Abdulraouf A, Burris SJ, Langlieb J, Gazestani V, Nadaf NM, et al. Single-cell genomic profiling of human dopamine neurons identifies a population that selectively degenerates in Parkinson's disease. Nat Neurosci. 2022 May;25(5):588-95. [Pubmed]
28. Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the diagnosis of Parkinson's disease. Lancet Neurol. 2021 May;20(5):385-97. [Pubmed]
29. Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015 Oct;30(12):1591-601. [Pubmed]
30. Rizzo G, Copetti M, Arcuti S, Martino D, Fontana A, Logroscino G. Accuracy of clinical diagnosis of Parkinson disease: A systematic review and meta-analysis. Neurology. 2016 Feb 9;86(6):566-76. [Pubmed]
31. Berg D, Borghammer P, Fereshtehnejad SM, Heinzel S, Horsager J, Schaeffer E, Postuma RB. Prodromal Parkinson disease subtypes - key to understanding heterogeneity. Nat Rev Neurol. 2021 Jun;17(6):349-61. [Pubmed]
32. Qian E, Huang Y. Subtyping of Parkinson's Disease - Where Are We Up To? Aging Dis. 2019 Oct 1;10(5):1130-9. [Pubmed]
33. Mestre TA, Fereshtehnejad SM, Berg D, Bohnen NI, Dujardin K, Erro R, et al. Parkinson's Disease Subtypes: Critical Appraisal and Recommendations. J Parkinsons Dis. 2021;11(2):395-404. [Pubmed]
34. Monje MHG, Foffani G, Obeso J, Sánchez-Ferro Á. New Sensor and Wearable Technologies to Aid in the Diagnosis and Treatment Monitoring of Parkinson's Disease. Annu Rev Biomed Eng. 2019 Jun 4;21:111-43. [Pubmed]
35. Lieberman A, Deep A, Shi J, Dhall R, Shafer S, Moguel-Cobos G, et al. Downward finger displacement distinguishes Parkinson disease dementia from Alzheimer disease. Int J Neurosci. 2018 Feb;128(2):151-4. [Pubmed]
36. Fereshtehnejad SM, Zeighami Y, Dagher A, Postuma RB. Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression. Brain. 2017 Jul 1;140(7):1959-76. [Pubmed]
37. Erro R, Picillo M, Vitale C, Palladino R, Amboni M, Moccia M, et al. Clinical clusters and dopaminergic dysfunction in de-novo Parkinson disease. Parkinsonism Relat Disord. 2016 Jul;28:137-40. [Pubmed]
38. Hasin Y, Seldin M, Lusis A. Multi-omics approaches to disease. Genome Biol. 2017 May 5;18(1):83. PMID: 28476144. [Pubmed]
39. Mitchell T, Lehéricy S, Chiu SY, Strafella AP, Stoessl AJ, Vaillancourt DE. Emerging Neuroimaging Biomarkers Across Disease Stage in Parkinson Disease: A Review. JAMA Neurol. 2021 Oct 1;78(10):1262-72. [Pubmed]